Co-Managing the Diabetic Patient -

The live program has concluded.

If you attended, please click on the "Take Post-Test" button to claim your credit. If you did not attend, please stay tuned for the archived version, which will be available soon for on-demand viewing.

Scroll back to top

Details

Overview
Diabetes is a growing epidemic in the United States, and diabetic macular edema (DME) and diabetic retinopathy (DR) poses a substantial risk for vision loss if not diagnosed and/or treated. It remains clear that although diabetes is a systemic disorder, the manifestations of diabetic complications will occur without optimal glycemic and blood pressure control. Optometrists can help continually reinforce that message by educating patients about the necessity for ongoing and yearly dilated eye exams, and discussing the potential treatments should vision loss become obvious.Grantor Statement This CE activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals, Inc. Sponsor Statement This CE activity is supported by The University of Houston College of Optometry
Learning Objectives
Target Audience This activity intends to educate optometrists.
Learning Objectives Upon completion of this activity, participants should be better able to:
- Determine who is a high-risk patient for the onset of diabetic eye disease
- Discuss the importance of conducting yearly dilated exams on diabetic patients
- Develop plans to initiate co-management of the diabetic patient with both ophthalmologists and primary care physicians/endocrinologists
- Implement strategies to educate patients on the ocular manifestations of diabetes
Accreditation
This course is COPE approved for 1.0 hour of CE credit for optometrists.
COPE Course ID: 49883-SD
COPE Event ID: 111606
Faculty and Disclosures
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
Mark Dunbar, OD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Allergan, Inc.; Carl Zeiss Meditec and Regeneron Pharmaceuticals, Inc.
Paul Chous, OD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Bausch & Lomb Incorporated; CooperVision; Freedom Meditech, Inc.; Regeneron Pharmaceuticals, Inc.; and ZeaVision, LLC and Grant/Research Support: ZeaVision, LLC
Leo Semes, OD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Allergan, Inc.; Optovue, Inc.; and Regeneron Pharmaceuticals, Inc. and Stock/Shareholder: HPO
Cheryl Cavanaugh, MS; Michelle Dalton and Melanie Lawler, PhD have no relevant commercial interests to disclose.
Disclosure Attestation Each of the contributing faculty listed above has attested to the following:
1.       That the relationships/affiliations noted will not bias or otherwise influence his or her involvement in this activity;
2.       That practice recommendations given relevant to the companies with whom he or she has relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice; and
3.       That all reasonable clinical alternatives will be discussed when making practice recommendations.
Disclaimer
Off Label Disclosure
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Expiration Date: 06/30/2017